NCT03608631View on ClinicalTrials.gov

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
KRAS NP_004976.2:p.G12DMetastatic Pancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
DRUG

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03608631 - iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Biotech Hunter | Biotech Hunter